# A Study of Ciltacabtagene Autoleucel and Talquetamab for the Treatment of Participants With High-Risk Multiple Myeloma

Source: https://onco.cc/trials/nct06550895/  
OnCo record `nct06550895` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Ciltacabtagene autoleucel, Talquetamab in multiple myeloma, run by Janssen Research & Development, LLC, active and no longer recruiting.

## Summary

A Study of Ciltacabtagene Autoleucel and Talquetamab for the Treatment of Participants With High-Risk Multiple Myeloma is a phase 2 interventional study registered as NCT06550895 by Janssen Research & Development, LLC, with 11 participants enrolled, started 2024-09-16 and due to reach its primary completion in 2027-08-26. Interventions recorded: Cilta-cel, Talquetamab. Conditions listed: Multiple Myeloma. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT06550895
- Phase: 2
- Setting: A Phase 2, Open-Label, Multicenter Study of Ciltacabtagene Autoleucel and Talquetamab for the Treatment of Participants With High-Risk Multiple Myeloma
- Sponsor: Janssen Research & Development, LLC
- Enrolled: 11

## Sources

- ClinicalTrials.gov NCT06550895: https://clinicaltrials.gov/study/NCT06550895

## Connected records

- cancers: [Multiple myeloma](https://onco.cc/cancers/multiple-myeloma/)
- drugs: [Ciltacabtagene autoleucel](https://onco.cc/drugs/ciltacabtagene-autoleucel/), [Talquetamab](https://onco.cc/drugs/talquetamab/)
- companies: [Johnson & Johnson](https://onco.cc/companies/johnson-johnson/)

---
JSON: https://onco.cc/api/v1/entities/nct06550895.json